Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

Author's Avatar
Jan 09, 2023

Spruce+Biosciences%2C+Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).